C.R. Bard, Inc. (NYSE:BCR) insider Sharon M. Luboff sold 30,252 shares of the company’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $320.00, for a total value of $9,680,640.00. The sale was disclosed in a filing with the SEC, which is accessible through this link.

C.R. Bard, Inc. (NYSE BCR) opened at 320.06 on Thursday. The firm has a market cap of $23.26 billion, a PE ratio of 42.02 and a beta of 0.58. The firm has a 50-day moving average price of $319.90 and a 200-day moving average price of $304.42. C.R. Bard, Inc. has a one year low of $203.63 and a one year high of $324.58.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The firm had revenue of $979.70 million during the quarter, compared to analyst estimates of $976.53 million. During the same quarter in the previous year, the company posted $2.54 earnings per share. The company’s revenue was up 5.2% compared to the same quarter last year. On average, equities analysts expect that C.R. Bard, Inc. will post $11.81 EPS for the current fiscal year.

WARNING: “C.R. Bard, Inc. (BCR) Insider Sells $9,680,640.00 in Stock” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/10/05/c-r-bard-inc-bcr-insider-sells-9680640-00-in-stock.html.

Several analysts recently weighed in on the company. Jefferies Group LLC restated a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a research report on Thursday, September 14th. BidaskClub downgraded C.R. Bard from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Zacks Investment Research downgraded C.R. Bard from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Finally, BMO Capital Markets reaffirmed a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $292.00.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in shares of C.R. Bard by 70.4% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock worth $145,000 after buying an additional 190 shares during the period. Parallel Advisors LLC increased its holdings in shares of C.R. Bard by 283.8% in the first quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock worth $153,000 after buying an additional 369 shares during the period. ClariVest Asset Management LLC purchased a new position in shares of C.R. Bard in the first quarter worth about $148,000. SRS Capital Advisors Inc. increased its holdings in shares of C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock worth $148,000 after buying an additional 4 shares during the period. Finally, Captrust Financial Advisors purchased a new position in shares of C.R. Bard in the second quarter worth about $192,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Insider Buying and Selling by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.